SCHEDULE: Balyasny Asset Management Discloses 7.6% Stake in Contineum

Balyasny Asset Management and its affiliates have reported a 7.6% beneficial ownership stake in Contineum Therapeutics, Inc.'s Class A Common Stock.

Summary

• Balyasny Asset Management L.P. and its affiliated entities, including BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny, collectively reported beneficial ownership of 2,312,800 shares of Contineum Therapeutics, Inc. Class A Common Stock.
• This ownership represents approximately 7.60% of the Class A Common Stock outstanding, based on 30,446,111 shares as of December 12, 2025, as reported in the Issuer's Prospectus on Form 424B5.
• The shares are held directly by Atlas Diversified Master Fund, Ltd. (ADMF), an investment management client of Balyasny Asset Management L.P.
• The Reporting Persons, through their various organizational roles, are deemed to exercise voting and investment power over these shares.
• The acquisition of these securities was made in the ordinary course of business and not for the purpose of changing or influencing the control of Contineum Therapeutics, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant stake by a reputable institutional investor like Balyasny Asset Management can indicate confidence in Contineum Therapeutics, Inc.'s future prospects.

Positives

• A significant institutional investor, Balyasny Asset Management, has taken a 7.60% stake in Contineum Therapeutics, Inc., indicating potential confidence in the company's prospects.
• The investment is stated to be in the ordinary course of business, suggesting a long-term investment perspective rather than an activist stance.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

StockSavvy.ai notes that the disclosure of a significant stake by a prominent hedge fund like Balyasny Asset Management in a biotechnology or pharmaceutical company such as Contineum Therapeutics, Inc. often signals institutional interest and potential validation of the company's long-term strategy or pipeline. Such filings can attract further investor attention to the stock.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially lead to increased trading volume or positive share price movement.
• Management: The presence of a large institutional investor may lead to increased scrutiny or engagement from the investor regarding corporate strategy and performance.

Key Dates

Recommendation

While the disclosure of a significant stake by a respected institutional investor like Balyasny Asset Management is generally a positive indicator, a Schedule 13G filing alone does not provide sufficient fundamental information about Contineum Therapeutics, Inc.'s operations, financials, or strategic direction to warrant a 'buy' or 'sell' recommendation. It suggests institutional confidence, but investors should conduct further due diligence on the company's core business before making investment decisions. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive signal while awaiting more comprehensive data.

Keywords

Contineum Therapeutics, Inc., Balyasny Asset Management, CTNM, Schedule 13G, Beneficial Ownership, Institutional Investment, Class A Common Stock, Equity Stake, Investment Management